Impact Founder
Asian/Pacific Founder
First-Time FounderActively RaisingAbout
Hiba Therapeutics is developing AND-logic gated, targeted therapies against cancers, autoimmune diseases and age-associated fibrosis by clearing aberrant cells by harnessing tissue-resident immunity. The company's TROIKA platform is a modular, programmable technology with inbuilt specificity and safety features designed to eliminates aberrant cancer and senescent cells that drive disease.
Traction & Metrics
Fundraising
$500K
Previous Round
Products
HIB-101
AND-logic gated immunotherapy platform for reversing age-associated fibrosis by targeting senescent myofibroblasts. The TROIKA platform features three key components: tissue targeting via antibody, tissue-specific linker for functional targeting, and T cell activation module. Designed to harness tissue-resident immunity to selectively eliminate aberrant disease-causing cells with minimal systemic toxicity. Lead program HIB-101 targets idiopathic pulmonary fibrosis (IPF) with expansion potential into fibrotic liver disease (NASH) and IBD/Crohn's disease.
Click to read more
Updates
Hiba Therapeutics wins Chiesi Air USA 2026 golden ticket
We’re excited to announce that Hiba Therapeutics Inc. has been selected as the winner of the Chiesi Air USA 2026 golden ticket. https://www.linkedin.com/posts/biolabs_biolabsgoldenticket-ugcPost-7462958427946942464-u14V